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Summary N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic
acid (ICI D1694) is an analogue of the thymidylate synthase inhibitor, N'°-propargyl-5,8-dideazafolic acid
(CB3717). CB3717 was found to be active in early clinical studies, but its use was limited by nephrotoxicity.
ICI D1694 is a more potent antitumour agent than CB3717 and is also more water soluble. Previous studies
have shown ICI D1694 to be non-toxic to the kidney following a single administration but its renal effects
after chronic administration are unknown. To assess these effects, and further define the time course and dose
relationship of CB3717-induced renal damage, an assay of glomerular filtration rate (GFR) has been
developed which can be used in mice and hence in the screening of novel compounds. The '4C-inulin clearance
assay developed was used to show a linear relationship between CB3717 dosage and renal damage
(r=-0.989) following a single bolus dose (50-200mgkg-'), in mice. CB3717-induced renal damage is
persistent (>6 weeks) and renal scarring was noted. ICI D1694 has been shown to be non-nephrotoxic
following weekly administration of 250 mg kg- ' for 6 weeks. Measurement of GFR has been shown to be a
more sensitive indicator of impaired renal function than plasma urea and creatinine concentration, and the
measurement of plasma creatinine concentration in particular, appears to be without value in the screening of
potential nephrotoxins in certain mouse strains.
Nl'-propargyl-5,8-dideazafolic acid (CB3717, Figure l.i.) is a
folate based inhibitor of the enzyme thymidylate synthase
(TS), which was found to be an active antitumour agent in
early clinical trials in patients with breast, ovarian and hepa-
tocellular carcinoma (Calvert et al., 1986; Cantwell et al.,
1988; Bassendine et al., 1987). However, the clinical use of
CB3717 was limited by its nephrotoxicity, which was observ-
ed in Phase I studies of both weekly (Vest et al., 1988) and
3-weekly administration schedules (Calvert et al., 1986; Sessa
et al., 1988). Renal toxicity manifested primarily as a reduc-
tion in glomerular filtration rate (GFR). However, tubular
damage was also identified by the measurement of the urin-
ary enzymes, N-acetyl glucosaminidase (NAG) and leucine
aminopeptidase (LAP). A >20% reduction in GFR was
observed in seven of 12 (58%) patients receiving more than
400mgm2 CB3717. In addition, urinary NAG and LAP
levels were elevated in 50% of patients studied, although this
elevation was not dose related (Calvert et al., 1986).
CB3717-induced nephrotoxicity was thought to be due to
the compound's relative insolubility at acid pH. However,
despite adequate alkalinisation (pH ,8) of the urine, reduc-
tions in GFR (measured using creatinine clearance) of
>20%, were still seen in 6/17 (35%) courses in patients
treated at 400 mg m2 (Sessa et al., 1988). To circumvent
toxicity related to drug precipitation in the kidney, a series of
more soluble analogues of CB3717 have been synthesised. In
addition to being devoid of renal toxicity in acute testing,
a number of these compounds are more potent cytotoxic
agents in vitro and retain antitumour activity in vivo (Harrap
et al., 1989). One such analogue, N-(5-[N-(3,4-dihydro-2-
methyl- 4 -oxoquinazolin- 6 -ylmethyl)- N-methylamino]-2-the-
noyl) L-glutamic acid (ICI D1694, Figure lii) has been
selected for preclinical development (Jackman et al., 1991).
The plasma concentrations of urea and creatinine are com-
monly measured to assess renal function during toxicological
screening of new drugs. However, these parameters are rela-
tively insensitive, because, in mice, a rise in plasma urea and
creatinine concentration only occurs following the loss of
70-75% offunctional renal mass (Everett & Harrison, 1983).
Specificity is also poor because an elevation in plasma urea
may be caused by 'pre-renal' (increased protein catabolism,
gastric or intestinal bleeding and dehydration) or 'post-renal'
(obstruction to renal outflow) causes, as well as parenchymal
renal damage (Everett & Harrison, 1983). In patients treated
with high dose cisplatin, attention has been drawn to the
potential underestimation of the degree of renal damage by
assessing renal function using serum creatinine levels alone
(Daugaard et al., 1988). In man, the measurement of GFR
has become accepted as a routine method for the assessment
of renal function. The classical technique using inulin, which
is solely cleared from the plasma by glomerular filtration,
involves its constant infusion with simultaneous urine collec-
tion (Jones, 1985). However, in mice, a constant infusion of
inulin and simultaneous urine collection would require anaes-
thesia or rigid restraint and complete emptying of the bladder
before and at completion ofthe test (Ragan, 1989). Therefore
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Figure 1 The structures of (i) CB3717 and (ii) ICI D1694.
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it is clearly unsuitable for routine toxicology screening. To
simplify the measurement of GFR, the use of a single bolus
injection, and the measurement of inulin clearance using a
limited number of samples, has been studied and shown to
correlate well with the classical method (Rosenbaum et al.,
1973). It is also possible to measure GFR using a single
timed sample provided the volume of distribution (V) of the
tracer is known (Bryan et al., 1972). Renal clearance is
calculated using the equation: Clearance = V (log&(PO/Pt)/t),
where t = time of sample, P0 and Pt = Plasma tracer concen-
tration at to and t. It is necessary to ascertain the volume of
distribution for the tracer in the particular strain and sex of
the species used for screening. It is then possible to assess the
GFR of an individual animal from the dose administered and
the plasma concentration at a single time point t, (P,),
because P0 = Dose/V (provided t is in the elimination phase
of tracer clearance).
In order to define the nephrotoxicity of CB3717 and assess
the effects on the kidney following the repeat administration
of ICI D1694 an assay using '4C labelled inulin and a single
timed plasma sample was developed and validated. Since
cisplatin is a well documented nephrotoxin (Von Hoff et al.,
1979) it was used to validate the assay system and the results
obtained were compared with plasma urea and creatinine
concentrations, the classical markers for nephrotoxicity.
Following validation of the assay, studies were performed to
assess the renal impairment associated with both single and
repeated administration of CB3717. Finally studies were per-
formed to assess the effects on the kidney of repeated admin-
istration of the novel TS inhibitor chosen for clinical
development, ICI D1694.
Materials and methods
The measurement ofglomerularfiltration rate (GFR) in mice
In order to define the volume of distribution of '4C-inulin, in
female Balb C and in male C57/DBA2 Fl hybrid mice,
'4C-inulin pharmacokinetics were studied in normal mice.
Balb C mice are routinely used in the testing of platinum
antitumour agents and C57/DBA2 mice in the testing of
quinazoline TS inhibitors at the Institute of Cancer Research.
'4Carbon labelled inulin (Amersham International PLC,
Amersham, UK) with a specific activity of 2-10 mCi mmol-',
was dissolved in PBS (0.01 M Na2PO4 pH 7.48) to give a
5SACi ml-' injection solution. Mice were briefly warmed to
<40'C and '4C-inulin was administered intravenously (iv)
(0.01 ml g-' = 0.05 jiCi g' body weight), via a tail vein at
time to. Five mice were killed at time points predicted to fall
in the elimination phase of inulin clearance i.e. 30, 40, 50 and
60 min. Following CO2 asphyxiation, blood was collected by
open cardiac puncture in a heparinised syringe. 0.1 ml of
separated plasma was added to 1.0 ml of mixed quaternary
ammonium hydroxides in toluene (NCS solubiliser, Amer-
sham Corp., Illinois, USA) in a glass scintillation vial and
incubated (40°C) overnight. NCS was neutralised by 0.04 ml
acetic acid (17.45 M). Ten ml of scintillant (Emulsifier Safe,
Hewlett Packard, Downers Grove, IL, USA) was added and
radioactivity was measured by liquid scintillation (Hewlett
Packard TRI-CARB Counter, 2000CA). Data obtained were
then analysed by non-linear least squares regression analysis
(Jennrich & Samson, 1968), using a weighting function of
1/(y + 9)2. A monoexponential equation (C = Ae"') was fit
to the data giving A (the plasma concentration at to = Po)
and a(the rate constant). A was used to calculate the volume
of distribution (V) using A = Dose/V. Inulin clearance and
hence GFR was calculated using; Clearance = Va.
In drug treated mice, 0.05 IACi g-' body weight of 14C-
inulin was administered iv at to and plasma '4C-inulin con-
centration measured at 60 min(t), a time point shown to be
in the elimination phase of '4C-inulin clearance (see results).
The GFR in individual animals was calculated using Clear-
ance = V (log,(PO/Pt)/t). Group results are expressed as the
mean ± 1 s.d. -and compared using the Student's t-test. A
comparison giving P<0.05 was considered to be a signi-
ficant difference.
Validation ofthe GFR assay using cisplatin
Cisplatin (kindly provided by Johnson Matthew Research
Group, Sonning, UK) was dissolved in 0.9% NaCl. Cisplatin
8 mg kg-', a dosage known to be nephrotoxic (Siddick et al.,
1986), was administered by intraperitoneal (ip) injection to
Balb C mice. GFR was measured (as above) 4 days after
cisplatin administration. Plasma urea and creatinine concen-
trations were measured using a COBAS BIO autoanalyser
(Roche Diagnostics, Welwyn Garden City, UK) and com-
mercially available kits (Boehringer Mannheim (urea) and
Roche Diagnostics (creatinine)). These results were compared
with those obtained from age matched untreated controls.
Investigation of CB3717-induced nephrotoxicity, following a
single dose
CB3717 (1O mg ml' as disodium salt in NaHCO3, ICI Phar-
maceuticals) was administered ip to groups (n = 5) of C57/
DBA2 mice at 100 mg kg-', a dosage known to be nephro-
toxic (Newell et al., 1982). Renal function was assessed 1, 3,
5, 7, 14, 20 and 42 days after the administration of CB3717.
To establish the relationship between CB3717 dose and
renal toxicity, a range of CB3717 dosages (10, 50, 100 and
200 mg kg-') were administered as a single ip bolus. GFR
was measured 5 days (chosen following time course experi-
ment) after the administration of CB3717. Plasma urea and
creatinine concentrations were also measured (see above).
One kidney was removed and fixed (modified methacarn;
60% methanol, 30% Inhibisol (Kalon PLC, Cramlington,
UK) and 10% acetic acid) prior to sectioning, staining (hae-
matoxylin and eosin) and histological review, which was
performed without prior knowledge of treatment details.
Renalfunctionfollowing repeated administration ofCB3717
andICID1694
CB3717 or ICI D1694 were administered by ip injection. ICI
D1694 was supplied as a yellow powder and dissolved in
0.05 M NaHCO3. pH was adjusted to 9.0-9.5 using NaOH.
CB3717 (10 and 100 mgkg-') was administered weekly for 6
weeks and renal function assessed 1 week after the final dose.
ICI D1694 was similarly administered at 100 and 250 mg
kg' week'1. Renal function was assessed by GFR estima-
tion, plasma urea and creatinine concentrations. Kidney
tissue was prepared and examined histologically, as described
above.
Results
Theplasmapharmacokinetics of'4C-inulin
The plasma clearance of '4C-inulin, in both C57/DBA2 and
Balb C mice, was fit by a single exponential decay (Figure 2).
The volume of distribution of inulin in male C57/DBA2 Fl
hybrid mice was calculated to be 405 and 389 ml kg-' body
weight, in two separate studies. When '4C-inulin concentra-
tions calculated by regression analysis were compared with
the observed concentrations, to estimate the precision of the
fit, linear regression (r) values of 0.986 and 0.951 were
obtained, indicating that the data were well described by a
single exponential term. The '4C-inulin clearance values, and
hence GFR, were 21.9 and 20.6 ml min' kg-' body weight
in the two studies. In female Ralb C mice the volume of
distribution, 219 ml kg-', was lower than in male C57/DBA2
hybrid mice and the GFR was also lower at 15.3mlmin'
kg-'.
Validation ofthe GFR assay using cisplatin
Four days after the administration ofcisplatin (8 mg kg-'), a
clear reduction in GFR was noted (Figure 3). This highlyTHE RENAL EFFECTS OF CB3717 AND ICI D1694, IN MICE 835
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Figure 2 '4C-inulin clearance in female Balb C (--O--, 15.3 ml
min' kg-') and male C57/DBA2 hybrid ( + -, 20.6 ml min'
kg-') mice, following bolus intravenous injection.
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significant (P<0.01) reduction in GFR (control, 14.7 ± 0.8
ml min'l kg-'; cisplatin 8 mg kg- ', 6.7 ± 1.6 ml min'l kg-')
was not associated with any significant rise in plasma urea
and creatinine concentrations (Figure 3).
Nephrotoxicity ofCB3717 after a single administration
GFR, plasma urea and creatinine concentrations and histo-
logical changes in the kidney were assessed up to 42 days
after the administration of CB3717 (100 mg kg-') (Table I).
A significant reduction in GFR was seen on day 3 and this
persisted, with one exception (day 14), in all assays per-
formed up to day 42. Plasma urea concentration was elevated
on days 3 to 14, but plasma.creatinine concentration was not
elevated at any stage. Histological examination was also
found to be a sensitive marker of renal damage and histo-
pathological damage evolved over the period of study. By
day 3, focal tubular dilatation was clearly visible (Plate 2)
when compared to the relatively normal histological appear-
ance following a low dose of CB3717 (10 mg kg-') shown in
Plate 1. Amorphous casts, which were thought to be drug
precipitates, were noted within the tubular lumina. These
casts persisted and were noted in sections, 20 days after
administration of CB3717 (Plate 3) and were still present at 6
weeks. Tubular dilatation persisted through days 5 and 7
with increased tubular mitotic activity, suggesting that repair
processes were commencing. By day 7 irregularities in the
cortex due to contraction of scar tissue were becoming
apparent. This contaction continued, and on day 20 depres-
sions in the cortex and glomerular atrophy were seen (Plate
4). Six weeks after administration of CB3717 deeply pitted
scars were clearly visible (Plate 5).
In addition plasma urea and creatinine concentrations were
assayed and histological examinations were performed at 9,
10, 11 and 14 weeks in a small number of animals. Plasma
biochemistry was normal in all these animals, however histo-
logical changes, such as cortical scarring and the presence of
amorphous casts, were still visible at 14 weeks.
When renal function was assessed 5 days after CB3717
administered at increasing dosages, a clear inverse linear
relationship (r = - 0.989) between the CB3717 dosage and
the degree of renal damage was observed (Figure 4). At
50mg kg', the reduction in GFR was significant (CB3717
50 mg kg-', 19.6 ± 1.2 ml min-' kg-'; control, 21.9 ± 1.5 ml
min- kg- ; 0.01 <P<0.05), but plasma urea concentration
was not significantly elevated (CB3717 50 mg kg-', 6.4 ±
0.6 gM; control 8.8 ± 1.5 gM). The reduction in GFR
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Figure 3 Renal function assessed 4 days after cisplatin (8 mg
kg-' ip). Data shown are mean± I s.d. (n = 5).
Table I Renal function up to 42 days after 100mgkg-' CB3717 as a
single bolus
Time post GFR Urea Creatinine
injection (days) (mlmin-'kg-') (mM) (tLM)
Control 23.1±2.0 10.1±1.0 72±19
1 24.4±2.3 9.1±1.3 64±14
3 16.7±3.9b 17.4±4.4a 72± 10
5 18.1±3.4b 16.6±6.ob 67± 9
7 17.7± 3.6b 13.4±3.3a 61± 7
14 23.9± 2.0 13.2± 2.2a 57± 3
20 18.9±2.ob 10.4± 1.2 50± 4
42 19.6±1.6b 15.0±3.3 50± 3
Data shown are mean± 1 s.d. (n = 5). aoo.i <P<0.05; bP0.01.
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Plate 1 ( x 60 H&E) Relatively normal histological appear- Plate 4 ( x 60 H&E) Early, mild cortical scarring with glome-
ance of the kidney 5 days after a single low dose of CB3717 rular atrophy in the scars, 20 days after a single dose of CB3717
(0mg kg-'). (100mgkg-').
Plate 5 ( x 60 H&E) Deep cortical scars, 42 days after a single
dose of CB3717 (100 mgkg-').
Plate 2 ( x 60 H&E) Kidney section, 3 days after a single dose
of CB3717 (100 mgkg-'), showing tubular dilatation.
c ._d
cr
Plate 3 ( x 240 H&E) Kidney section to show the tubular
casts persisting 20 days after a single dose of CB3717 (100mg
kg-').
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Figure 4 The apparent linear relationship (r = - 0.989) between
glomerular filtration rate (GFR) and CB3717 dosage administer-
ed 5 days prior to GFR estimation. Data shown are mean± 1 s.d.
(n = 5).THE RENAL EFFECTS OF CB3717 AND ICI D1694, IN MICE 837
increased with CB3717 dosage, but only at CB3717 (200 mg
kg-1) was a significant rise in urea concentration (24.2 ± 4.5
pM) and creatinine concentration (CB3717, 200 mg kg-',
85 ± 8 iAM; control 67 ± 10 lOM) observed. This was the only
study described in this paper where an elevation in creatinine
concentration was noted. Histological examination demon-
strated focal tubular dilatation following CB3717, 50mgkg-'
and these changes were observed over increasingly extensive
areas of the kidney as the CB3717 dosage increased to 100
and 200mgkg-'.
Renalfunction after repeatedadministration ofCB3717 or ICI
D1694
When CB3717 100mg kg-' was administered weekly for 6
weeks, a significant (P<0.01) reduction in GFR was observ-
ed 1 week after the final dose (17.7 ± 3.1 ml min"' kg-';
control, 21.6 ± 1.1 ml min-' kg-'). Plasma urea concentra-
tion appeared to be elevated in these animals (CB3717,
11.5 ± 4.3 control, 8.5 ± 0.9) but this result was not signi-
ficant (P>0.05). Cortical scarring with tubular dilatation
and amorphous casts were also noted, on histological exam-
ination of the kidneys.
In contrast, following the administration of ICI D1694
100 mg kg- weekly for 6 weeks, there was no evidence of
renal damage as assessed by biochemical analyses and GFR
estimation (Table II). In addition there was no histological
evidence of renal damage following this schedule. The dosage
of ICI D1694 was increased to 250 mgkg' weekly for 6
weeks and GFR remained unchanged when compared to
control (Table II) and again histological examination was
normal in 5/5 mice.
Discussion
The studies described in this paper were designed to further
define the nephrotoxicity caused by CB3717 and to assess the
renal effects associated with the repeated administration of
ICI D1694. It was first necessary to develop and validate an
assay for glomerular filtration rate (GFR), applicable to
mice.
The plasma pharmacokinetics of '4C-inulin were studied
in C57/DBA2 hybrid mice. The similarity of the results
obtained in the two separate studies in untreated mice was
encouraging as it demonstrated the reproducibility and hence
reliability of the assay. If the values observed for the GFR in
control mice of this strain in each of the various studies
discussed in this paper are compared, they are also similar
(23.0 ± 1.9 mlmin'i kg-', mean ± s.d., n = 25), providing
further confirmation of reproducibility. This mean value is
identical to that quoted for mannitol clearance, and hence
GFR, in a review of mouse physiology (Kaplan et al., 1983).
However, the volume of distribution of '4C-inulin in C57/
DBA2 mice was higher than might have been predicted.
Inulin is commonly used to demonstrate the extracellular
fluid (ECF) volume which comprises 18-25% ofbody weight
(i.e '200 ml kg-') in mammals (Prosser, 1973) and the
values obtained for C57/DBA2 mice were clearly higher than
TableII Renalfunction 1 weekafterrepeatedweeklydosesofCB3717
and ICI D1694
Compound and GFR Urea
(dose andschedule) (mlmin ' kg-') (mM)
Control 21.6±1.1 8.5±0.9
CR3717 21.8±2.1 Not done
(10mgkg-' weekly x 6)
CB3717 17.7±3.la 11.5±4.3
(100 mgkg-' weekly x 6)
ICI D1694 21.6±1.5 9.3±1.1
(100 mg kg-' weekly x 6)
ICI D1694 21.6±1.4 9.5±0.7
(250 mg kg-' weekly x 6)
Data shown are mean± 1 s.d. (n = 5). aP<0.01.
this (405 and 389 mlkg-'). However, this may be a function
of strain or sex, since the volume of distribution of '4C-inulin
measured in female Balb C mice (219 mlkg-'), relates more
closely to the predicted ECF volume.
The studies with cisplatin demonstrate the potential bene-
fits of GFR estimation as a measure of renal function. Cis-
platin is a known nephrotoxin (Von Hoff et al., 1979) and yet
impairment of renal function would not have been detected
in the present study if measurement of plasma urea and
creatinine concentrations had been used alone. In contrast,
the measurement of GFR clearly identified the impairment in
renal function (Figure 3), and this mirrors experience report-
ed from studies in man (Daugaard et al., 1988). The data
presented above demonstrate the low detection rate which
may result if biochemical parameters alone are used to screen
for nephrotoxicity. Indeed, creatinine was only significantly
elevated following the administration of CB3717 at a dosage
of 200 mg kg-', a dosage which caused a >70% reduction in
GFR (Figure 4). These findings must seriously question the
value of measuring serum creatinine in screening for nephro-
toxicity. In contrast, the importance of including histological
examination in a screening programme was highlighted, since
this demonstrated abnormalities when both biochemical
parameters and GFR were not statistically different from
control.
The nephrotoxicity induced by CB3717 has been defined in
detail. Histological examination following a single dose of
CB3717 100 mgkg-', identified tubular dilatation 24 h after
administration of the drug. These changes were seen to pro-
gress, with infiltration of inflammatory cells into the affected
areas and subsequent repair with scar formation. It is notable
that although obvious histological changes were seen, these
were focal and data from the GFR estimations show that
there was only a small deterioration in renal function. It is
surprising that there was no clear evidence of cumulative
renal impairment associated with repeated dosing, even at
100mgkg-' (Table II). This suggests that the kidney can
compensate for the CB3717 damage, possibly by hyperplasia,
as is seen in the remaining kidney following nephrectomy.
It has been shown that in man CB3717 can cause renal
damage (reduction in GFR) at doses as low as 10 mgm2,
when the drug is administered by bolus injection at weekly
intervals (Vest et al., 1988). It was thought that this reduc-
tion of GFR seen at low doses of CB3717 may be caused by
a mechanism other than drug precipitation in the renal
tubules, i.e. one which may be related to the anti-metabolic
effects of CB3717, mediated by inhibition of thymidylate
synthase. However, in the studies in mice reported here,
similar nephrotoxicity following repeated low dose adminis-
tration was not seen. A single dose of 10 mg kg-' (30 mgm-2)
CB3717 was associated with a normal GFR and histological
examination was also normal and when CB3717 1Omg kg-'
was administered weekly, a schedule resembling that used by
Vest et al., there was also no reduction in GFR, when
measured 1 week after completion of 6 weekly injections
(Table II).
The persistence of amorphous casts in the renal tubules
following CB3717 (100mgkg'1) was probably due to drug
precipitates (Plate 3), although clearly this is not proven by
the data presented. However, it should be noted that in
studies with radiolabelled CB3717, radioactivity was still
detectable in the kidneys of mice 23 days after administration
of the compound (Newell et al., 1986). In addition, a clear
dose relationship for CB3717 and the extent of renal damage
has been identified (Figure 4), using both GFR measurement
and histological examination. In particular, an inverse linear
relationship (r = - 0.989) was shown between dose and GFR.
The absence of acute renal toxicity following single bolus
doses of 500mgkg-' of ICI D1694 has been reported pre-
viously (Jodrell et al., 1990). It is therefore encouraging that
the studies reported here also show no evidence of renal
toxicity following repeated weekly dosing with ICI D1694 at
100 and 250 mgkg-', and support the hypothesis that
CB3717 induced renal toxicity was due to its relative insolu-
bility at physiological pH. It is therefore unlikely that838 D.I. JODRELL et al.
nephrotoxicity will be encountered in clinical studies with ICI
D1694.
In summary, CB3717-induced nephrotoxicity has been de-
fined and shown to be dose related with an inverse linear
relationship between dose and GFR. Irreversible histological
changes are seen following a single bolus dose of CB3717. In
contrast ICI D1694, a more water soluble analogue of
CB3717, has been shown to be non-nephrotoxic following
both single (Jodrell et al., 1990) and repeated administration.
Measurement of GFR has been shown to be a more sensitive
indicator ofimpaired renal function than the measurement of
plasma urea and creatinine concentration and the role of
creatinine estimation in the screening of novel compounds as
potential nephrotoxins is questioned.
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